Scribe Therapeutics files for IPO in test of public appetite for earlier-stage biotechs
Scribe Therapeutics seeks $75 million in an IPO, testing market appetite for early-stage biotech.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
Scribe Therapeutics, an Alameda-based company specializing in gene-editing and cardiovascular disease treatments, has filed for a proposed initial public offering on the Nasdaq. The company aims to raise $75 million through the listing, with notable existing stockholders including Eli Lilly.
Coverage from Renaissance Capital, The Business Journals, and Investing.com highlights the firm's focus on cholesterol-fighting treatments and gene-editing technology. Endpoints News frames the filing as a significant test of public investor sentiment toward earlier-stage biotech companies.
Future coverage is expected to clarify the proposed share price range and the specific use of proceeds for the $75 million offering. Reports do not yet specify the ticker symbol or the timing of the IPO pricing.
Synthesized by PULSE from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 66d ago.
Quick answers
What is Scribe Therapeutics?
It is an Alameda-based biotech company focused on gene-editing and treatments for cardiovascular diseases and high cholesterol.
How much does the company plan to raise?
The company filed for a proposed $75 million IPO.
Who backs Scribe Therapeutics?
Current stockholders include Eli Lilly, though a full list of investors is not specified in the coverage.
Coverage (5)
- SCTX IPO News - Cardiovascular diseases biotech Scribe Therapeutics files for a $75 million IPO renaissancecapital.com · 69d ago
- Meet the gene-editing, cholesterol-fighting Alameda company looking for IPO riches The Business Journals · 69d ago
- Scribe Therapeutics files for proposed Nasdaq IPO By Investing.com Investing.com South Africa · 69d ago
- Scribe Therapeutics Stockholders Include Eli Lilly Moomoo · 69d ago
- Scribe Therapeutics files for IPO in test of public appetite for earlier-stage biotechs Endpoints News · 69d ago
Topics
Related trends
Nasdaq Invests in Kraken Parent Payward at $21 Billion Valuation
Nasdaq invests $100 million in Kraken parent Payward at a $21 billion valuation to advance tokenized equities.
Costco set to expand with 14 new warehouses across US and Canada
Costco is accelerating its footprint across North America with the planned opening of 14 new warehouse locations in the United States and Canada.
Shopify acquires Tailwind Labs (SHOP:NASDAQ)
Shopify has acquired Tailwind Labs to bolster its custom storefront capabilities and expand its strategic ecosystem for merchants.
Dow tumbles 400 points, posting 3-day slide as rates jump and Brent crude tops $101: Live updates
Financial markets extend a losing streak as major stock indexes fall, treasury yields rise, and oil prices cross notable thresholds.
What to Know About Anthropic’s Planned IPO
Anthropic is preparing for an initial public offering amid concerns regarding pricing strategies and market competitiveness.
How Novartis' Double-Stacked Failures Shook Biotech
Investor's Business Daily reports on how Novartis' double-stacked failures shook the broader biotech sector.